Atrial Fibrillation News and Research

RSS
Atrial fibrillation (AF) is the most common arrhythmia. An arrhythmia is a problem with the speed or rhythm of the heartbeat. A disorder in the heart’s electrical system causes AF and other types of arrhythmia. AF occurs when rapid, disorganized electrical signals in the heart’s two upper chambers, called the atria, cause them to contract very fast and irregularly (this is called fibrillation). As a result, blood pools in the atria and isn’t pumped completely into the heart’s two lower chambers, called the ventricles. When this happens, the heart’s upper and lower chambers don’t work together as they should. Often, people who have AF may not even feel symptoms. However, even when not noticed, AF can lead to an increased risk of stroke. In many patients, particularly when the rhythm is extremely rapid, AF can cause chest pain, heart attack, or heart failure. AF may occur rarely or every now and then, or it may become a persistent or permanent heart rhythm lasting for years.
Warfarin therapy provides substantial protection for elder patients with atrial fibrillation

Warfarin therapy provides substantial protection for elder patients with atrial fibrillation

Merlin.net Patient Care Network launched in Europe

Merlin.net Patient Care Network launched in Europe

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

Clinical trial results of Dabigatran proves its effectiveness for treating atrial fibrillation

New trial data shows that BIOTRONIK monitoring system is safe and effective for detecting patients' clinical events

New trial data shows that BIOTRONIK monitoring system is safe and effective for detecting patients' clinical events

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Phase 2B clinical trial results of oral vernakalant to be presented at the ESC Congress 2009

Phase 2B clinical trial results of oral vernakalant to be presented at the ESC Congress 2009

St. Jude Medical opens first Advanced Learning Center in Brussels

St. Jude Medical opens first Advanced Learning Center in Brussels

New rule from CMS for improving stroke patient care in hospitals

New rule from CMS for improving stroke patient care in hospitals

Blood thinner warfarin may have opposite effects in kidney disease patients on dialysis

Blood thinner warfarin may have opposite effects in kidney disease patients on dialysis

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

European Medicines Agency accepts reviewal of Merck's MAA for regulatory approval of vernakalant IV

Cardiome Pharma's board authorizes buyback of shares

Cardiome Pharma's board authorizes buyback of shares

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

The Society of Chest Pain Centers announces a new grant program to encourage clinical research

The Society of Chest Pain Centers announces a new grant program to encourage clinical research

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

Mount Sinai Medical Center physicians pioneer a non-surgical procedure for treating LAA

National Science Foundation funds CMU for developing revolutionary computational tools

National Science Foundation funds CMU for developing revolutionary computational tools

Aryx Therapeutics reports Q2 2009 financials

Aryx Therapeutics reports Q2 2009 financials

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Health Canada approves Multaq (Dronedarone) for atrial fibrillation

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Additional trial to be conducted for KYNAPID under FDA special protocol agreement

Decode Genetics announces Q2 2009 financials

Decode Genetics announces Q2 2009 financials